159 related articles for article (PubMed ID: 21831963)
41. Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203) in ovarian cancer.
Callero MA; Luzzani GA; De Dios DO; Bradshaw TD; Perez AI
J Cell Biochem; 2013 Oct; 114(10):2392-404. PubMed ID: 23696052
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one.
Ciolino HP; MacDonald CJ; Yeh GC
Cancer Res; 2002 Jul; 62(13):3685-90. PubMed ID: 12097275
[TBL] [Abstract][Full Text] [Related]
43. Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.
Presa D; Khurram SA; Zubir AZA; Smarakan S; Cooper PA; Morais GR; Sadiq M; Sutherland M; Loadman PM; McCaul J; Shnyder SD; Patterson LH; Pors K
Sci Rep; 2021 Sep; 11(1):18930. PubMed ID: 34556703
[TBL] [Abstract][Full Text] [Related]
44. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells.
Spink DC; Spink BC; Cao JQ; DePasquale JA; Pentecost BT; Fasco MJ; Li Y; Sutter TR
Carcinogenesis; 1998 Feb; 19(2):291-8. PubMed ID: 9498279
[TBL] [Abstract][Full Text] [Related]
45. CYP2S1 depletion enhances colorectal cell proliferation is associated with PGE2-mediated activation of β-catenin signaling.
Yang C; Li C; Li M; Tong X; Hu X; Yang X; Yan X; He L; Wan C
Exp Cell Res; 2015 Feb; 331(2):377-86. PubMed ID: 25557876
[TBL] [Abstract][Full Text] [Related]
46. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2.
Kuffel MJ; Schroeder JC; Pobst LJ; Naylor S; Reid JM; Kaufmann SH; Ames MM
Mol Pharmacol; 2002 Jul; 62(1):143-53. PubMed ID: 12065765
[TBL] [Abstract][Full Text] [Related]
47. Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.
McLean LS; Watkins CN; Campbell P; Zylstra D; Rowland L; Amis LH; Scott L; Babb CE; Livingston WJ; Darwanto A; Davis WL; Senthil M; Sowers LC; Brantley E
Chem Res Toxicol; 2015 May; 28(5):855-71. PubMed ID: 25781201
[TBL] [Abstract][Full Text] [Related]
48. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.
Karlgren M; Gomez A; Stark K; Svärd J; Rodriguez-Antona C; Oliw E; Bernal ML; Ramón y Cajal S; Johansson I; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2006 Mar; 341(2):451-8. PubMed ID: 16426568
[TBL] [Abstract][Full Text] [Related]
49. Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells.
Thomas RD; Green MR; Wilson C; Weckle AL; Duanmu Z; Kocarek TA; Runge-Morris M
Chem Biol Interact; 2006 Apr; 160(3):204-16. PubMed ID: 16527260
[TBL] [Abstract][Full Text] [Related]
50. Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4' hydroxy tangeretin.
Surichan S; Arroo RR; Tsatsakis AM; Androutsopoulos VP
Toxicol In Vitro; 2018 Aug; 50():274-284. PubMed ID: 29626627
[TBL] [Abstract][Full Text] [Related]
51. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.
Bradshaw TD; Westwell AD
Curr Med Chem; 2004 Apr; 11(8):1009-21. PubMed ID: 15078163
[TBL] [Abstract][Full Text] [Related]
52. Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX.
Meng LH; Shankavaram U; Chen C; Agama K; Fu HQ; Gonzalez FJ; Weinstein J; Pommier Y
Cancer Res; 2006 Oct; 66(19):9656-64. PubMed ID: 17018623
[TBL] [Abstract][Full Text] [Related]
53. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.
Yang C; Zhou Q; Li M; Tong X; Sun J; Qing Y; Sun L; Yang X; Hu X; Jiang J; Yan X; He L; Wan C
Sci Rep; 2016 Sep; 6():33078. PubMed ID: 27609465
[TBL] [Abstract][Full Text] [Related]
54. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells.
Döhr O; Vogel C; Abel J
Arch Biochem Biophys; 1995 Aug; 321(2):405-12. PubMed ID: 7646066
[TBL] [Abstract][Full Text] [Related]
55. Characterization and expression of extrahepatic CYP2S1.
Deb S; Bandiera SM
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):367-80. PubMed ID: 19368491
[TBL] [Abstract][Full Text] [Related]
56. The CYP2W1 enzyme: regulation, properties and activation of prodrugs.
Guo J; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Drug Metab Rev; 2016 Aug; 48(3):369-78. PubMed ID: 27257736
[TBL] [Abstract][Full Text] [Related]
57. Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?
Pan Y; Ong EC
Xenobiotica; 2017 Oct; 47(10):923-932. PubMed ID: 27690753
[TBL] [Abstract][Full Text] [Related]
58. Effects of zearalenone on mRNA expression and activity of cytochrome P450 1A1 and 1B1 in MCF-7 cells.
Yu Z; Hu D; Li Y
Ecotoxicol Environ Saf; 2004 Jun; 58(2):187-93. PubMed ID: 15157572
[TBL] [Abstract][Full Text] [Related]
59. RNA expression of cytochrome P450 in Mexican women with breast cancer.
Bandala C; Floriano-Sánchez E; Cárdenas-Rodríguez N; López-Cruz J; Lara-Padilla E
Asian Pac J Cancer Prev; 2012; 13(6):2647-53. PubMed ID: 22938436
[TBL] [Abstract][Full Text] [Related]
60. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
